Table 1.
Baseline characteristics according to cardiac damage.
| All patients (n = 1,133) |
Stage 0 or 1 (n = 151) |
Stage 2 (n = 397) |
Stage 3 (n = 239) |
Stage 4 (n = 346) |
omnibus p-value | |
|---|---|---|---|---|---|---|
| Age (years) | 82.1 ± 6.3 | 80.5 ± 6.6 | 82.7 ± 5.5 | 83.1 ± 5.7 | 81.4 ± 7.2 | <0.001 |
| Gender (female) | 576 (50.8%) | 82 (54.3%) | 190 (47.9%) | 155 (64.9%) | 149 (43.1%) | <0.001 |
| Body surface area (m2) | 1.82 ± 0.23 | 1.82 ± 0.24 | 1.85 ± 0.23 | 1.80 ± 0.23 | 1.81 ± 0.22 | 0.029 |
| STS-PROM | 6.07 ± 4.22 | 4.32 ± 2.70 | 5.37 ± 3.38 | 6.89 ± 5.05 | 7.08 ± 4.59 | <0.001 |
| NYHA III or IV | 775 (68.5%) | 88 (58.3%) | 258 (65.2%) | 167 (69.9%) | 262 (75.9%) | <0.001 |
| Hypertension | 946 (83.5%) | 123 (81.5%) | 338 (85.1%) | 202 (84.5%) | 283 (81.8%) | 0.543 |
| Chronic kidney disease (eGFR < 60) | 809 (71.5%) | 91 (60.3%) | 270 (68.0%) | 184 (77.0%) | 264 (76.5%) | <0.001 |
| Coronary artery disease | 715 (63.1%) | 89 (58.9%) | 243 (61.2%) | 142 (59.4%) | 241 (69.7%) | 0.023 |
| History of cerebrovascular accident | 135 (11.9%) | 12 (7.9%) | 57 (14.4%) | 29 (12.1%) | 37 (10.7%) | 0.170 |
| Peripheral artery disease | 170 (15.0%) | 20 (13.2%) | 56 (14.1%) | 37 (15.5%) | 57 (16.5%) | 0.742 |
| COPD | 162 (14.3%) | 18 (12.0%) | 55 (13.9%) | 38 (16.0%) | 51 (14.8%) | 0.717 |
| Previous Cardiac Surgery | 203 (17.9%) | 13 (8.6%) | 59 (14.9%) | 29 (12.1%) | 102 (29.5%) | <0.001 |
| Previous pacemaker implantation | 111 (9.8%) | 8 (5.3%) | 27 (6.8%) | 29 (12.1%) | 47 (13.6%) | 0.002 |
| Mitral stenosis (≥moderate) | 45 (4.4%) | 4 (2.8%) | 16 (4.4%) | 11 (5.3%) | 14 (4.7%) | 0.725 |
STS-PROM = Society of Thoracic Surgery Predicted Risk Of Mortality; NYHA = New York Heart Association; eGFR = estimated glomerular filtration rate; COPD = chronic obstructive pulmonary disease.